Company Update - MorphoSys

BYM338: HuCAL Antibody for the
Unintentional Weight Loss in Cancer Patients
Efficacy, Safety and Tolerability of BYM338 in Patients With
Sporadic Inclusion Body Myositis
Status Phase 2 (recruiting)
Study Design
Study Start Date August 2011
Completion Date December 2011
Enrollment 12
Primary
Outcome
Measures
Secondary
Outcome
Measures
Randomized, double-blind, placebo-controlled
study
Assessment of the affect of BYM338 on thigh
muscle volume by MRI (time frame: 8 weeks)
Assessment of the effect of BYM338 on muscle
function by 'Timed Get Up and Go' test
(Time frame: 8 weeks)
Patients Patients with sporadic Inclusion Body Myositis
Clinical Study of BYM338 for the Treatment of Unintentional
Weight Loss in Patients With Cancer of the Lung or the
Pancreas
Status Phase 2 (recruiting)
Study Design
Study Start Date August 2011
Completion Date September 2012
Enrollment 50
Primary
Outcome
Measures
Secondary
Outcome
Measures
Patients
Randomized, double-blind, placebo-controlled
study
Increase in thigh muscle volume as measured by
MRI (Time Frame: 8 Weeks)
� 6 minute walk test (Time frame: 8 weeks)
� Efficacy in treating unintentional weight loss
(Time frame: 8 weeks)
� Obtain pharmacokinetic data in this population
(Time frame: 8 weeks)
� Efficacy in improving total lean body mass
(LBM) and total bone mineral content
(Time frame: 8 weeks)
� Improving physical activity and function
(Time frame: 8 weeks)
Patients With Stage IV Non-small Cell Lung
Cancer or Stage III/IV Adenocarcinoma of the
Pancreas
© MorphoSys AG
Page 34